Results from International Trial of Second Sight’s Argus® II Retinal Prosthesis System Published in Ophthalmology
Published: Feb 07, 2012
LOS ANGELES and LAUSANNE, Switzerland--(BUSINESS WIRE)--Second Sight Medical Products, Inc., the world’s leading developer of retinal prostheses for the blind, announced positive interim results from a single-arm, controlled, prospective, multicenter clinical trial of its Argus II Retinal Prosthesis. The six-month results will be published in the April edition of the leading peer-reviewed journal Ophthalmology, the journal of the American Academy of Ophthalmology. Argus II gained European market approval in February 2011, the only retinal prosthesis in the world to achieve this status. The European market approval of this class of medical devices requires a demonstration of safety and performance with long-term clinical testing, and compliance to strict quality standards.